Director Alex Gibney explores how Purdue Pharma worked closely with the FDA to approve OxyContin for widespread use, touting its safety without evidence and campaigning to redefine pain treatment. In the face of insufficient government intervention, Purdue continued to prioritize profit over addiction, creating a market for even deadlier opioids.

While pharmaceutical companies mass-market the synthetic opioid fentanyl, lawmakers continue to grease the opioid pipeline.